Press release archive 2010-2016
Oncopeptides Receives the SwedenBIO Award 2017
May 17, 2017
For the 11th time, SwedenBIO Award was awarded on Wednesday night.
Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)
March 27, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
ABG Sundal Collier AB exercises the over-allotment option regarding 977,906 shares in Oncopeptides AB (publ)
March 24, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected
March 22, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today
February 22, 2017
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
Notice to attend an extraordinary shareholders’ meeting in Oncopeptides AB (Publ)
January 4, 2017
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan...
Oncopeptides Welcomes New Board Member – Luigi Costa
August 15, 2016
Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors.
Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016
July 7, 2016
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with r...
Oncopeptides prepare for pivotal Phase 3 clinical trials
April 30, 2016
Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical tr...
Oncopeptides have a successful meeting with MHRA
March 31, 2016
Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients.
Oncopeptides CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma
January 13, 2016
Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.
Oncopeptides presents latest efficacy results of melflufen in combination with dexamethasone at ASH
December 11, 2015
Oncopeptides AB, a clinical stage company developing a peptidase potentiated therapy – melflufen – presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed refra...
Results Presented at EHA Show Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with Melflufen and Dexamethasone
June 12, 2015
Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated wit...
Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015
June 4, 2015
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of m...
Oncopeptides Receives EMA and FDA Orphan Drug Designation for Melflufen in the Treatment of Multiple Myeloma
March 23, 2015
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both ...
Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and RelapsedRefractory Multiple Myeloma at the 56th ASH Annual Meeting and Exposition
December 5, 2014
Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion ...
Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
August 20, 2013
Stockholm, Sweden August 20, 2013 – Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myel...
Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients
May 21, 2013
Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; m...
Oncopeptides AB appoints Jakob Lindberg as CEO
October 21, 2011
STOCKHOLM, SWEDEN - October 21, 2011. Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Mo...
Oncopeptides AB. Presents the New Anticancer Agent J1 at The American Society of Hematology Annual Meeting in Orlando, Florida
December 1, 2010
STOCKHOLM, SWEDEN – 1 December 2010 – Oncopeptides AB today announced that preclinical results for J1 will be presented this week-end at the ASH Annual Meeting in Orlando, Florida, USA. The abstract 1...
Oncopeptides Announce New Chairman of the Board
April 19, 2010
STOCKHOLM, April 19, 2010 - Oncopeptides AB, today announced that Alan Hulme was elected Chairman of the Board at the statutory annual meeting. Mr Hulme has over 30 years experience in the life scienc...